Eczema Free Foreverâ„¢ Eczema Free Foreverâ„¢

Breakthrough Drugs Boost Treatment Options for Eczema – NY1


NY1
Breakthrough Drugs Boost Treatment Options for Eczema
NY1
Alexandra Ilyashov doesn't know what triggered her eczema a year and a half ago. It came suddenly, and severly, spreading all over her body. "It was, you know, first maybe the limbs and then suddenly the entire abdomen, chest, back, buttocks," she said

eczema – Google News

Breakthrough Drugs Boost Treatment Options for Eczema – NY1


NY1
Breakthrough Drugs Boost Treatment Options for Eczema
NY1
Alexandra Ilyashov doesn't know what triggered her eczema a year and a half ago. It came suddenly, and severly, spreading all over her body. "It was, you know, first maybe the limbs and then suddenly the entire abdomen, chest, back, buttocks," she said

eczema – Google News

I prescribe drugs off-label. Am I in violation of FDA regulations

In a CME session through your local dermatology society, a prominent drug company provides journal articles documenting the off-label use of one of their prescription pharmaceutical agents. You obtain CME credits, read the journal article and begin prescribing the off-label medication. Is the drug company in violation of the U.S. Food and Drug Administration (FDA) rulings? Are your actions acceptable?
Dermatology Times – Dermatology

Drugs in Perspective: Otezla (apremilast)

Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Modern medicine – American Academy of Dermatology